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Abstract: Sham surgery is used as a control condition in
neurosurgical clinical trials in Parkinson’s disease (PD) but
remains controversial. This study aimed to assess the perspec-
tive of patients with PD and the general public on the use of
sham surgery controls. We surveyed consecutive patients from
a university-based neurology outpatient clinic and a communi-
ty-based general internal medicine practice. Background infor-
mation was provided regarding PD and two possible methods
of testing the efficacy of a novel gene transfer procedure,
followed by questions that addressed participants’ opinions
related to the willingness to participate and permissibility of
blinded and unblinded trial designs. Two hundred eighty-eight
(57.6%) patients returned surveys. Patients with PD expressed
less willingness to participate in the proposed gene transfer
surgery trials. Unblinded studies received greater support, but a
majority would still allow the use of sham surgery. Those in
favor of sham surgery were more educated and more likely to
use societal perspective rationales. Patients with PD are more
cautious about surgical research participation than patients with
non-PD. Their policy views were similar to others’, with a
majority supporting the use of sham controls. Future research
needs to determine whether eliciting more considered judg-
ments of laypersons would reveal different levels of support for
sham surgery. © 2007 Movement Disorder Society
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The use of placebo or sham surgery controls in ran-
domized trials of surgical interventions is becoming
more common in Parkinson’s disease (PD) research1-5
but is not without controversy.6 Aside from questions
surrounding informed consent, the controversy over
sham surgery controls involves two predominant issues.
The first is whether a randomized clinical trial with sham
surgery control is a scientifically superior method to test
novel neurosurgical interventions for PD. PD researchers
believe that a placebo surgery should be used as a control
condition when testing a novel surgical intervention.7
Second, are the risks to subjects in randomized clinical
trials with sham surgery controls reasonable in relation to
the potential benefit to the subjects and to society? Some
of the risks associated with sham surgery in PD have
been summarized,8 but the opinion of whether the risks
and burdens associated with sham surgery are too high
requires input from the patients who are the potential
study participants.
Patients who are currently experiencing the symptoms
of PD may be better able to compare the risks and
benefits and best answer whether the risks to individuals
is worth the benefit to science and society. Therefore, we
developed a hypothetical scenario describing a gene
transfer intervention with promising initial results and
surveyed patients regarding their views on the use of
sham surgery as the placebo in controlled surgical trials.
PATIENTS AND METHODS
Participants
From May 24, 2004 through September 9, 2004, we
surveyed consecutive patients with and without PD from
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a neurology clinic with a high proportion of patients with
PD. Patients with dementia were excluded. As a com-
parison group, the survey was also administered to pa-
tients from a community-based general internal medicine
practice.
Survey Instrument
The survey consisted of four pages of background
information followed by three questions. We described
the motor symptoms typically reported in moderate to
advanced PD. We then presented a scenario detailing a
hypothetical gene transfer intervention. The respondents
were asked to suppose that a successful phase I study of
a novel gene transfer therapy for PD had been conducted
on eight subjects. They were told, “The researchers did
not find any significant short-term negative effects from
the gene transfer and there was some evidence that gene
transfer surgery reduced PD symptoms.” Second, they
were asked to consider two potential randomized, con-
trolled trial designs for a follow up study involving 40
subjects, the goal of which was to test the efficacy and
safety of the gene transfer procedure. The first possibility
was an open, unblinded study in which 20 subjects would
be randomized to receive gene transfer surgery plus their
usual medications or usual medications only. In the sec-
ond possible hypothetical trial, 20 subjects would be
randomized to undergo gene transfer surgery or sham
surgery, in which sham surgery consisted of drilling two
full thickness burr holes. For the sham controlled study,
the respondents were told that if the gene transfer surgery
turned out to be safe and effective, “the participants who
undergo sham surgery will [later] be offered the gene
transfer procedure using the predrilled holes.” The de-
scription concluded with a discussion of the scientific
reasoning behind using placebo surgery and an explana-
tion of the potential risks and benefits of gene transfer
therapy for PD.
Participants were asked to imagine that they them-
selves had moderate to advanced PD as described in the
survey. They were then asked if they would participate in
an unblinded study, a blinded study, or not participate at
all in a gene transfer trial. The second question asked
participants to suppose they were members of an ethics
review committee whose job it is to decide whether to
allow certain studies. The purpose of this exercise was to
frame the question from a societal perspective in order to
distinguish the decision from a personal preference per-
spective. They then decided whether they would allow an
unblinded study and a blinded study. Finally, they were
asked if the burdens and risks of sham surgery to subjects
were justified by the potential benefits to society. Partic-
ipants could justify their choices immediately after an-
swering each question. For question one (“which study
would you participate in?”), we provided a list of six
options based on consistent responses from previous
studies to justify the decision. For the other questions,
participants were prompted to justify decisions with an
open-ended question.
Analysis
We tabulated frequency data and analyzed the quali-
tative data from the open comments as follows. Two of
the authors (SK and RW) read all the comments together
and devised a coding scheme that was later modified
with input from two other authors (RH and SF). For each
question, we categorized comments with similar content
related to individual questions. Each comment was inde-
pendently coded by three of the authors; the final code
was assigned when there were two of three or better
agreement. When coding the 758 comments, agreement
among at least two of three coding judges occurred in
93.1% of cases and the rest were resolved by consensus
meeting. Some respondents made lengthy comments that
required more than one code per comment.
Except for age, the data were categorical, and there-
fore all unadjusted comparisons were performed using 2
tests of independence for the two-way contingency ta-
bles. Age was compared using ANOVA. Multiple logis-
tic regression was used to compare the three patient
groups (PD, non-PD neurology, primary care), adjusted
for age group (5-year groupings between ages 40 and 70,
and treating “not reported” as a separate category), gen-
der, education (high school or less, some college, college
degree, post college degree), marital status (married,
unmarried), and potential two-way interactions. Separate
binary logistic regression models were fit for each of five
binary outcomes: (1) would participate versus would not
participate in any surgical trial, (2) participate in blinded
versus open (excluding those who would not participate),
(3) allow open versus not allow open, (4) allow sham
surgery versus not allow sham, and (5) the risks are or
are not worth the potential benefit to society. To simplify
the final models, adjacent categories of ordered categor-
ical covariates were collapsed. Once the functional forms
of the main effect terms were selected, all-subsets regres-
sion was again used to consider all possible two-way
interactions between the remaining predictors. To make
the same modeling adjustments in all five final models,
any predictor that was selected for one outcome was
retained for the others as well. In the final models, the
Wald test (df  2) was used to test whether patient group
was independent of each outcome, adjusted for the de-
mographic covariates, and odds ratios with correspond-
ing 95% confidence intervals and P-values were used to
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summarize adjusted differences between pairs of patient
groups.
All subsets analysis selected four age groups (50,
50–64, 65, and “not reported”), three education levels
(high school or less, some college or a college degree,
post college degree), and both gender and marital status
were retained. There was insufficient evidence to justify
the inclusion of any interaction terms.
Human Subjects
The University of Rochester and the University of
Michigan reviewed the protocol and deemed this survey
exempt from IRB review.
RESULTS
Three hundred surveys were distributed at the neurol-
ogy clinic and 200 surveys at the primary care clinic.
One hundred sixty-nine (56.3%) and 119 (59.5%) sur-
veys were returned from the neurology and primary care
clinics, respectively. Among the neurology clinic partic-
ipants, the patient diagnoses included PD (33.1%), dys-
tonia (9.5%), essential tremor (6.5%), huntington disease
(2.4%), and others (35.5%). 88.5% of patients answered
all questions. The lowest response rate for any single
question was 94.6% except age, which had a response
rate of 76.4%.
Patients with PD were older, with a female majority,
and more patients with PD were married when compared
with the other groups (Table 1). Patients with PD were
less willing to participate in the proposed trials (Table 2).
34% of patients with PD stated that they would not
participate in either of the hypothetical gene transfer
surgery trials, compared to 6.4% of the patients with
non-PD neurology and 10.4% of the primary care pa-
tients (2  26.0, df  4, P  0.001).
When asked to give their views, supposing they were
members of an ethics review committee, most of the
respondents, regardless of group, favored allowing both
the sham surgery study and the open study, although the
support for the open study was higher (Table 3). Com-
ments by the minority who opposed allowing the open
trial (17%) were predominantly “scientific” rationales,
with 61% pointing to the scientific inadequacy. Among
those who would allow the open study, 27% of com-
ments indicated that the risks were outweighed by the
overall benefit to science and society and 22% found
blinding per se objectionable. Comments by those in
TABLE 1. Characteristics of groups
PD Non-PD neurology Primary care All patients P*
n 56 113 119 288
Age (SD) 66.8 (10.0) 51.7 (15.8) 57.0 (9.2) 56.8 (13.4) 0.001
Gender 0.001
No. (%) of females 32 (60.4) 76 (68.5) 100 (84.7) 208 (73.7)
Education (no./%) 0.13
High school or less 15 (27.3) 19 (17) 14 (11.9) 48 (16.8)
Some college 15 (27.3) 27 (24.1) 27 (22.9) 69 (24.2)
College degree 9 (16.4) 32 (28.6) 34 (28.8) 75 (26.3)
Post college 16 (29.1) 34 (30.4) 43 (36.4) 93 (32.6)
Ethnicity (no./ %) 0.26
White 55 (98.2) 110 (98.2) 107 (92.2) 272 (95.7)
Black 1 (1.8) 1 (0.9) 6 (5.2) 8 (2.8)
Other 0 1 (0.9) 3 (1.6) 4 (1.4)
Marital status (no./%) 0.002
Married 48 (85.7) 71 (63.4) 77 (65.8) 196 (68.7)
Divorced/separated 4 (7.1) 17 (15.2) 22 (18.8) 43 (15.1)
Single/never married 0 21 (18.8) 11 (9.4) 32 (11.2)
Widowed 4 (7.1) 3 (2.7) 7 (6.0) 14 (4.9)
Missing data is due to participants not providing answers to demographic questions.
*2 tests were used for comparisons of categorical data; ANOVA used for comparison of continuous data.
TABLE 2. Which study would you choose to participate in?
PD Non-PD neurology Primary care Total
Unblinded n (%) 22 (41.5) 60 (55) 63 (54.8) 145 (52.5)
Blinded n (%) 13 (24.5) 42 (38.5) 40 (34.8) 95 (34.4)
Would not participate n (%) 18 (34)a 7 (6.4) 12 (10.4) 37 (13.4)
aP  0.001, 2  26.0, df  4
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favor of the blinded (i.e., sham) study tended to be
comparative value statements that appeared to reflect a
balancing of opposing considerations, or pointed to the
role of informed consent as justifying the study. Those
opposed to sham control design, on the other hand,
tended to focus on the invasive, risky nature per se
(rather than using comparative value statements), fo-
cused on the risk-benefit for the participants only, or
were opposed to blinding or sham surgery in general.
When asked if the burdens and risks of surgery with-
out expectation of benefit to the subject was justified by
the potential benefits to science and to society, 56% of





care Total Comments (% of responses)
Suppose you are a member
of an ethics review
committee. . .Would
you allow the






44 (81.4) 95 (85.6) 96 (81.4) 235 (83) An unblinded study could lead to progress in
research or provide useful information and
the risk to subjects is acceptable in
comparison to potential benefits for
science and society (27%)
It is better if group assignment is transparent
and subjects are informed of whether they
are receiving gene or not (22%)
The control group faces less risk than with
sham surgery (11%).
Definitely or probably not
allow
10 (18.5) 16 (14.4) 22 (18.6) 48 (16.9) There is too high a chance of the placebo
effect and bias with the unblinded design
(37%)
The results from an unblinded study would
not be as scientifically sound and
conclusive (24%)
The risk-benefit ratio associated with the
unblinded design is unacceptable (7%)
Do not approve of any study involving
surgery (7%).
Would you allow the
blinded (sham surgery
control design) study




30 (54.6) 60 (53.5) 64 (54.7) 154 (54.3) The blinded study is the only way to get
definitive, conclusive results (24%)
The blinded design is acceptable if adequate
informed consent is in place (20%)
The risk-benefit ratio with the blinded study
is acceptable (18%)
The risks are outweighed by potential
benefits to society, subjects, and science
(18%).
Definitely or probably not
allow
25 (45.5) 52 (46.5) 53 (45.3) 130 (45.8) There is too much risk and the procedures
are too invasive (28%)
Asking the patients to accept risk without
benefit is unacceptable (25%)
The blinded design and use of sham surgery
is unethical (12%).
It is not ethical to ask people to participate
in a study where they do not know
whether they will receive the gene or not
(11%).
All responses are n (%) of the group.
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respondents thought the risk was justified, without sig-
nificant differences between the groups.
In the multiple logistic regression analyses, patient
group significantly predicted willingness to participate in
the proposed surgical trials (i.e., those willing to partic-
ipate in blinded or unblinded trial vs. those not willing to
participate in either surgical trial). The PD group was
significantly less willing to participate in either of the
proposed surgical trials compared to patients with
non-PD neurology [OR  0.10, 95% CI (0.03–0.33)]
and patients with primary care [OR  0.25, 95% CI
(0.09–0.68)] (P  0.001 on 2 df). Those with a post
college degree were more likely to approve of the use of
sham surgery controls under the hypothetical circum-
stances compared to subjects with a high school educa-
tion or less [OR  4.69, 95% CI (2.12–10.41)]. They
were also more likely to agree that for the proposed
trials, the burdens, and risks of sham surgery to subjects
are justified by the potential benefits to society [(OR 
3.66, 95% CI (1.59–8.42)].
DISCUSSION
When presented with a hypothetical case about research
involving gene transfer surgery, patients with PD expressed
less willingness to participate in the proposed surgical trials.
Patients with chronic illness adapt to their disabilities and
therefore, individuals with PD might feel they have less to
gain or more to lose from the benefits and risks associated
with trials involving surgery. Previous studies in PD have
confirmed this view, showing that severity of PD did not
predict willingness to participate in research.9 In fact, there
was some indication that more affected subjects were less
willing, consistent with adaptation playing a bigger role
than the intuition that more severe illness means more
willingness. Particular personality traits may also be present
in patients with movement disorders that increase risk aver-
siveness.10 Alternatively, patients with non-PD may over-
estimate the impact that PD disability may have on them or
underestimate retained function.11,12 Therefore, they may
assume more risk and overestimate the benefits of trials
involving surgery.
Using a hypothetical scenario evaluating a novel sur-
gical intervention for PD, most patients endorsed sham
surgery as an ethically acceptable control condition.
What distinguishes those who endorse sham surgery
from those who would not? Whether participants had PD
or not, education seems to play a strong role in people’s
willingness to take a more societal perspective and bal-
ance the burdens to participants with the overall scien-
tific and societal benefit. This trend is supported by the
qualitative comments given by those who would allow
sham surgery, as the supporters tended to give compar-
ative value statements. In contrast, those opposed to
sham surgery appeared to have an intrinsic objection to
blinding, and to focus on the invasive nature of the sham
procedure per se. It appears that those who are supportive
of sham controls are willing and able to understand and
take on a societal perspective in giving their answers,
whereas those who were opposed to it tend to focus on a
more narrow view or simply state their disapproval. This
finding raises important questions about whether further
intensive education and discussion about the scientific
rationales and the actual risks and benefits of sham
controls may affect people’s opinions. (For instance, a
recent review of the adverse effects of sham surgery in
four small PD trials did not find any serious adverse
events and no increased risk of adverse events compared
to the active intervention arms.8) Given the complexity
of the topic, it may be that laypersons, especially those
with less education, may need more opportunity to learn
and deliberate on the issues.
When comparing the responses of the subjects in this
study with PD researchers who were presented the same
hypothetical scenario, PD clinical researchers were more
skeptical about open studies (only 50% would allow it) and
more supportive of sham controlled studies (94% would
support it).7 However, it is notable that under the same
hypothetical circumstances, the patients who would allow
sham controls expressed similar reasoning for the permis-
sibility of sham surgery as the clinical researchers. Studies
are needed to determine if the gap between patients and
researchers can be closed if patients are given more in depth
education regarding clinical trial design, potential benefits
and possible risks to individuals and society, and are given
a chance to deliberate further on the issues or, conversely, if
researchers are further educated about issues of critical
importance to potential subjects.
There are several limitations of this study. First, we used
a hypothetical scenario requiring role-play for participants
without advanced PD. Further research is needed to confirm
our findings in patients actually considering trial participa-
tion and if these findings differ for different types of inva-
sive interventions with unique risk/benefit profiles. Second,
since participants were not examined for this study, there
was no measure of how many participants had to role-play
having advanced PD. Therefore, we cannot determine if
degree of disability affects responses. Third, compared to
the general PD population, a higher proportion of partici-
pants in this study were female, but ethnicity and education
level were comparable.13,14 In fact, a disproportionate num-
ber of women have participated in surgical trials involving
sham surgery (94 of 176, 53%).1-5 In addition, our multi-
variate analyses were adjusted for gender, and identified no
gender interactions, and thus findings can be interpreted to
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apply equally to both men and women. Fourth, the overall
response rate in this study was 57.6%, and the number of
nonresponders in all groups was similar. The subjects in this
study may have been biased and more inclined to partici-
pate in research since they chose to participate in this study.
Finally, general internal medicine and patients with non-PD
were used as comparison groups but may not necessarily
represent overall public views.
The nature of this study limits the ability to generalize
the findings in our study to patients in practice or to other
interventions with different risk and benefit profiles. The
participants for this study were not being recruited for
any other study and were specifically told so during the
consenting process. For the future, studies of persons in
actual clinical trials involving sham surgery may provide
further insight into this discussion.
In summary, patients with PD, when compared with
patients with non-PD neurology or primary care, may have
adapted to their chronic illness and may not be so desperate
that they would be more eager to participate in risky re-
search. In fact, they appear more cautious. Further, across
all three groups, although the support for an unblinded
study is higher than the blinded sham study, a majority
support the sham control study to test the efficacy of a
hypothetical novel gene transfer intervention. This support
appears to be related to higher educational background and
a willingness to compare and balance competing values
from a scientific and societal perspective.
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